Cyclo Therapeutics Inc (NASDAQ:CYTH)’s traded shares stood at 73.89 million during the latest session, with the company’s beta value hitting -0.57. At the last check today, the stock’s price was $0.99, to imply an increase of 28.47% or $0.22 in intraday trading. The CYTH share’s 52-week high remains $1.92, putting it -93.94% down since that peak but still an impressive 44.44% since price per share fell to its 52-week low of $0.55. The company has a valuation of $28.30M, with an average of 53740.0 shares in intraday trading volume over the past 10 days and average of 45.40K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cyclo Therapeutics Inc (CYTH), translating to a mean rating of 3.00. Of 3 analyst(s) looking at the stock, 1 analyst(s) give CYTH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
Cyclo Therapeutics Inc (NASDAQ:CYTH) trade information
After registering a 28.47% upside in the latest session, Cyclo Therapeutics Inc (CYTH) has traded red over the past five days. The 5-day price performance for the stock is 28.47%, and 52.18% over 30 days. With these gigs, the year-to-date price performance is 67.66%. Short interest in Cyclo Therapeutics Inc (NASDAQ:CYTH) saw shorts transact 0.11 million shares and set a 3.82 days time to cover.
The extremes give us $0.95 and $0.95 for target low and target high price respectively. As such, CYTH has been trading 4.04% off suggested target high and 4.04% from its likely low.
Cyclo Therapeutics Inc (CYTH) estimates and forecasts
Looking at statistics comparing Cyclo Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Cyclo Therapeutics Inc (CYTH) shares are -14.72% down over the last 6 months, with its year-to-date growth rate higher than industry average at 46.34% against 16.00%. The rating firms project that company’s revenue will shrink -10.23% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 322k. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 150k.Earnings reports from the last fiscal year show that sales brought in 311.4k and 202.45k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 3.40% before dropping -25.91% in the following quarter.
CYTH Dividends
Cyclo Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cyclo Therapeutics Inc (NASDAQ:CYTH)’s Major holders
Cyclo Therapeutics Inc insiders hold 40.08% of total outstanding shares, with institutional holders owning 13.17% of the shares at 21.98% float percentage. In total, 13.17% institutions holds shares in the company.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Cyclo Therapeutics Inc (CYTH) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 437.61 shares. This is just over 1.52% of the total shares, with a market valuation of $0.46 million. Data from the same date shows that the other fund manager holds a little less at 161.08, or 0.56% of the shares, all valued at about 0.17 million.
